Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib vs placebo in radioactive iodine-refractory differentiated thyroid cancer
CTR20180191Phase 3Terminated
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of donafenib in thyroid cancer, sponsored by Suzhou Zelgen Biopharmaceuticals. Started Mar 2018; status: terminated.
02
Drugs
donafenib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on CTR20180191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180191.